4.3400.58% ( +0.025 )
Delay Closed: Nov 16, 16:08:11Overview
GRANDPHARMA (512)
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations...
- Open
- 4.330
- High
- 4.415
- Low
- 4.290
- Prev. Close
- 4.315
- Volume
- 4.64M
- Turnover
- 20.20M
- Avg Price
- 4.354
- Bid/Ask Ratio
- -90.00%
- Amplitude
- 2.90%
- 52wk High
- 8.671
- Volume Ratio
- 0.85
- Turnover Ratio
- 0.13%
- 52wk Low
- 4.135
- HK Mkt Cap
- 15.41B
- Market CapHKD
- 15.41B
- P/ETTM
- 13.89
- P/EDynamic
- 7.26
- P/EStatic
- --
- EPSTTM
- 0.313
- EPSDynamic
- 0.598
- EPSStatic
- --
- BVPS
- 4.86
- P/B
- 0.89
- HK Shares
- 3.55B
- Dividend YieldTTM
- 3.89%
- DividendTTM
- 0.169
- Shares
- 3.55B
- Min lot size
- 500
- Currency
- HKD
GRANDPHARMA Analyst Rating
View moreForecast & Rating
Sep 8, 2026Price forecast
HK$9.53119.51%
Forecast & RatingStrong buy
4analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 4
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Jul, 2
远大医药 (512.HK) 今日大涨 8.7%,因肝癌创新药 DOORwaY90 试验结果积极,叠加公司获 8 亿港元贷款稳定股权结构。盘中低开于 4.940 港元后单边上行,午后触及 5.140 港元日高,收盘 5.110 港元,距 52 周低点 4.53 港元回升 12.8%,但较 52 周高点 9.89 港元仍跌 48.3%,且低于 MA60 的 5.764 港元。2025 年 Q4 营收同比增 10.3% 至 30.88 亿港元,但净利润暴跌 92.1% 至 3593 万港元,净利率仅 1.16%。PE14.6 倍、PB1.07 倍,股息率 3.31%。不过,前期利润预警及股价 YTD 跌 34.5% 仍构成压力。
